Showing results (1-10 of 390) with videos related to

Sort By:
Pageof 39
International Journal of Clinical Practice|February 8, 2002
The MRC/BHF Heart Protection Study: preliminary resultsRory Collins, Richard Peto, Jane Armitage
BMC Clinical Pharmacology|May 16, 2009
Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people, Jane Armitage, Louise Bowman, et al.
Lancet (London, England)|June 20, 2003
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialRory Collins, Jane Armitage, Sarah Parish, et al.
The British Journal of Nutrition|December 25, 2008
Plasma phospholipid fatty acids and CHD in older men: Whitehall study of London civil servantsRobert Clarke, Martin Shipley, Jane Armitage, et al.
Lancet (London, England)|March 16, 2004
Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditionsRory Collins, Jane Armitage, Sarah Parish, et al.
Circulation. Genomic and Precision Medicine|February 17, 2018
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE StudySarah Parish, Jemma C Hopewell, Michael R Hill, et al.
European Heart Journal|July 24, 2020
Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptomJemma C Hopewell, Alison Offer, Richard Haynes, et al.
The New England Journal of Medicine|September 4, 2008
Analyses of cancer data from three ezetimibe trialsRichard Peto, Jonathan Emberson, Martin Landray, et al.
BMJ (Clinical Research Ed.)|November 14, 2006
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people, Borislava Mihaylova, Andrew Briggs, et al.
Lancet (London, England)|May 25, 2005
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individualsBorislava Mihaylova, Andrew Briggs, Jane Armitage, et al.
Pageof 39